γδ T 细胞调节小细胞肺癌中的抗肿瘤免疫
γδ T cells modulate anti-tumor immunity in small cell lung cancer.
我们的发现表明,活化的γδ T细胞可能是SCLC治疗的有价值靶点。
英文原题:Novel growth pattern-specific digital marker of TILs improves stratification of lung adenocarcinoma patients.
我们的研究结果显示,GPS-TILs对总生存期具有强大的预后价值(p < 0.0001,C-index = 0.59),优于传统的基于TIL的指标和基于形态学的分层方法。
肺腺癌(LUAD)是最常见的癌症类型之一,尽管近年来癌症治疗取得了进展,其死亡率仍然居高不下。有效的风险分层对于指导治疗决策和加深对疾病机制的理解至关重要。然而,当前的预后评估方法面临相当大的局限性。基于生长模式的分级可作为肿瘤侵袭性的预后指标,但其本质上具有主观性,且观察者之间的变异性较高。其他成熟的预后指标,如TIL(肿瘤浸润淋巴细胞)(TILs)和间质TILs(sTILs)评分,虽能提供有价值的预后信息,但需要耗费大量人力进行评估。LUAD的显著异质性进一步增加了预后评估的复杂性,凸显了对能够同时捕捉肿瘤形态学和免疫学特征的稳健整合性生物标志物的需求。为满足这一需求,我们提出了一种基于AI的生长模式特异性TILs(GPS-TILs)标志物,该标志物分别量化每种生长模式内的TILs和sTILs。通过整合来自肿瘤生长模式的形态学信息和来自TILs的免疫微环境数据,我们证明所提出的GPS-TILs标志物改善了患者分层。我们在癌症基因组图谱LUAD(TCGA-LUAD)队列中,采用交叉验证设置下的Cox比例风险模型进行生存分析,评估了GPS-TILs的预后效用。我们的研究结果表明,GPS-TILs对总生存期具有强大的预后价值(p < 0.0001,C-index = 0.59),优于传统的基于TIL的指标和基于形态学的分层方法。这些结果突显了GPS-TILs作为一种更客观、更有效的工具,在改善LUAD患者风险分层方面的潜力。2025 The Author(s)。The Journal of Pathology由John Wiley & Sons Ltd代表大不列颠及爱尔兰病理学会出版。
Lung adenocarcinoma (LUAD) is one of the most prevalent forms of cancer and continues to be associated with high mortality rates, despite recent advances in cancer therapy. Effective risk stratification is critical for guiding treatment decisions and improving our understanding of disease mechanisms. However, current prognostic approaches face considerable limitations. Growth pattern-based grading serves as a prognostic indicator of tumour aggressiveness, but is inherently subjective and prone to a high degree of variability among observers. Other well-established prognostic indicators, such as tumour infiltrating lymphocytes (TILs) and stromal TILs (sTILs) scores, provide valuable prognostic information but require labour-intensive assessment. The pronounced heterogeneity of LUAD further complicates prognosis and underscores the need for robust, integrative biomarkers that capture both the morphological and immunological characteristics of the tumour. To address this need, we propose an AI-based growth-pattern-specific TILs (GPS-TILs) marker that quantifies TILs and sTILs within each growth pattern separately. By integrating morphological information from the tumour growth patterns and immune microenvironment data from TILs, we demonstrate that the proposed GPS-TILs marker improves patient stratification. We evaluated the prognostic utility of GPS-TILs using survival analysis with Cox proportional hazards models in a cross-validation setting using The Cancer Genome Atlas LUAD (TCGA-LUAD) cohort. Our findings revealed that GPS-TILs offers strong prognostic value for overall survival (p < 0.0001, C-index = 0.59), outperforming conventional TIL-based measures and morphology-based stratification approaches. These results highlight the potential of GPS-TILs as a more objective and effective tool for improving patient risk stratification in LUAD. 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
MEMBER ACCOUNT
登录成功会直接打开下一页。